Literature DB >> 6119205

Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.

M E Sharp, S M Wallace, K W Hindmarsh, M A Brown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6119205     DOI： 10.1007/bf00627927

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  23 in total

1.  Sulphasalazine rectal enemas: topical method of inducing remission of active ulcerative colitis affecting rectum and descending colon.

Authors:  H Serebro; S Kay; S Javett; C Abrahams
Journal:  Br Med J       Date:  1977-11-12

2.  High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.

Authors:  C Fischer; U Klotz
Journal:  J Chromatogr       Date:  1979-02-21

3.  Hemolysis during salicylazosulfapyridine therapy.

Authors:  P A van Hees; L W van Elferen; J M van Rossum; J H van Tongeren
Journal:  Am J Gastroenterol       Date:  1978-11       Impact factor: 10.864

4.  Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.

Authors:  T R Bates; H P Blumenthal; H J Pieniaszek
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

Review 5.  Chronic inflammatory bowel disease in children and adolescents: part I.

Authors:  J R Poley
Journal:  South Med J       Date:  1978-08       Impact factor: 0.954

6.  Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.

Authors:  J M Day; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

7.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

8.  Hemolytic anemia in patients receiving sulfasalazine.

Authors:  R L Goodacre; M A Ali; B Vanderlinden; J D Hamilton; M Castelli; T Seaton
Journal:  Digestion       Date:  1978       Impact factor: 3.216

9.  Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.

Authors:  T B Vree; W J O'Reilly; Y A Hekster; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

10.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059
View more
  3 in total

Review 1.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 2.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

Review 3.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.